"TOR"rents of excitement over rapamycin's antiepileptogenic potential

Comment

Lisa R Merlin. Epilepsy Curr. 2008 Nov-Dec.

. 2008 Nov-Dec;8(6):163-5.

doi: 10.1111/j.1535-7511.2008.00280.x.

No abstract available

Comment on

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.
Zeng LH, Xu L, Gutmann DH, Wong M. Zeng LH, et al. Ann Neurol. 2008 Apr;63(4):444-53. doi: 10.1002/ana.21331. Ann Neurol. 2008. PMID: 18389497 Free PMC article.
Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.
Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, Kwiatkowski DJ. Meikle L, et al. J Neurosci. 2008 May 21;28(21):5422-32. doi: 10.1523/JNEUROSCI.0955-08.2008. J Neurosci. 2008. PMID: 18495876 Free PMC article.

1. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991;253:905–909. - PubMed
1. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–484. - PubMed
1. Manis JP. Knock out, knock in, knock down – genetically manipulated mice and the Nobel Prize. New Engl J Med. 2007;357:2426–2429. - PubMed
1. Bockamp E, Maringer M, Spangenberg C, Fees S, Fraser S, Eshkind L, Oesch F, Zabel B. Of mice and models: Improved animal models for biomedical research. Physiol Genomics. 2002;11:115–132. - PubMed
1. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. New Engl J Med. 2006;355:1345–1356. - PubMed